In humans, insulin-like growth factor type 1 (IGF-1) and several of its binding proteins are positively associated with acquisition of PBM and the maintenance of bone mineral density (BMD) (911) and low IGF-1 levels have been found to be a risk factor for osteoporosis and fracture risk (3,1219)
This evolution in treatment highlights an urgent need for evidence that moves beyond weight loss alone to examine long-term cardiometabolic health, quality of life, and durability of treatment effects. Concerns about youth on GLP-1 According to Messiah, GLP-1 medications have demonstrated meaningful benefits for adolescents living with obesity, including substantial weight reduction and improvements in obesity-related conditions such as type 2 diabetes and hypertension, but she underscores that drugs need to be prescribed appropriately and accompanied by ongoing medical supervision
The safety and tolerability of semaglutide in this population will be elucidated in these trials
By reducing stomach volume, ESG helps patients feel full sooner and eat smaller portions
Concomitant use of an oral contraceptive with GLP1 agonist drugs (whether used for weight loss or type 2 diabetes) is going to be an increasingly common scenario and one we need to be mindful of
Diabetes Care 40(11):15881596 Lee DSU, Lee H (2022) Adherence and persistence rates of major antidiabetic medications: a review